ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Yodle, I have been researching BPAX and then ANIP since January 2012. Looking for the motive for not disclosing the CV risk reduction discovery laid out in the patent applications. I ahve alos written a few |Seeking Alpha articles on the topic

This one provides info on the biotech portion of ANIP acquired from BPAX during the merger. The company only advertises its present core business. You have to dig to learn about the BPAX side of the equation.

Why ANI Pharmaceuticals Should Outperform Short Term And Long Term

The following was written to promote discussion

Is LibiGel AbbVie's Little Secret?

Libigel Lowers Risk Of Breast Cancer And Cardiovascular Events. Who Benefits?

Here you have a post regarding an person named Linda Andrews who appeared to work simultaneously for Abbott Labs and Biosante at the same time from November 2009 to March 2010.

Coverup employee doctors Linkedin work history

Linda Andrews arrived on scene at Biosante at the time major changes were done to the clinical trials which led to the CV and Breast Cancer risk reduction discoveries.


In a conversation I had during the merger process with the CEO of BPAX, Stephen Simes, I asked about efficacy being obtained in the Larger 3656 patient safety/Efficacy study which he denied. Stating they were only looking at safety.

Simes not telling us everything


The article in the American Heart Journal entitled A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder contradicts Simes assertion. On three occasions the article was given free access and each time when I started posting about it, they put up the pay wall. The last time I figured they would do it again. So I saved it and posted it. It was funded by the money I and others put into BPAX. You will notice that two Biosante employees are given credit for the article. Including none other then Dr Michael Snabes who now works for Abbvie.

Highlighted in red you will see that contrary to teh CEO denying they were measuring efficacy. This article clearly states that efficacy was being measured. You will also notice that the number ofsurgically menopausal women is highlighted. If they maintained a similar ratio of enrollment for the rest of the trial they would have almost as many patients as much as the two efficacy trails combined

AHJ Article


Finally, the largest shareholder of ANIP, MVP Capital Partners, a subsidiary of Wells Fargo has holds two seats on the BOD voting the same shares. Can't help but think that one seat is simply being warmed for when Abbvie formalizes a partnership and takes a stake in Anip. (JMHO)

This should bring you up to speed with much ofthe longtime members on the board.

Happy reading